Evidence map›Paper›PMID 33145944›Full record

ArticleDiabetes, obesity & metabolism2021

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.

Moshe Phillip, Chantal Mathieu, Marcus Lind, Eiichi Araki, Paolo di Bartolo, Richard Bergenstal, Simon Heller, Lars Hansen, Markus Florian Scheerer, Fredrik Thoren and 5 more

Open access · bronzeAbstract readClinical Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trajectory of Kidney Function in T1D over Time: A Scoping Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 10 countries.

Moshe PhillipInstitute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.ORCID 0000-0002-6616-5612
Chantal MathieuClinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium.ORCID 0000-0002-4055-5233
Marcus LindDepartment of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-3796-9283
Eiichi ArakiDepartment of Metabolic Medicine, Kumamoto University, Kumamoto, Japan.
Paolo di BartoloRavenna Internal Medicine Department, Ravenna Diabetes Clinic, Romagna Local Health Authority, Ravenna, Italy.
Richard BergenstalInternational Diabetes Center, Health Partners Institute, Minneapolis, Minnesota, USA.
Simon HellerDepartment of Oncology and Metabolism, University of Sheffield School of Medicine, Sheffield, UK.ORCID 0000-0002-2425-9565
Lars HansenBioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Markus Florian ScheererBioPharmaceuticals Medical, AstraZeneca, Wedel, Germany.
Fredrik ThorenBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Niki AryaBioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
John XuBioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Nayyar IqbalBioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Paresh DandonaDepartment of Endocrinology, Kaleida Health, Buffalo, New York, USA.
DEPICT-1 and DEPICT-2 Investigators
AstraZeneca (Australia) · AUAstraZeneca (Finland) · FIAstraZeneca (Germany) · DEAzienda Unità Sanitaria Locale Della Romagna · ITHealthPartners · USKaleida Health · USKU Leuven · BEKumamoto University · JPNU Hospital Group · SETel Aviv University · ILUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the efficacy and safety of adjunct dapagliflozin therapy in patients with type 1 diabetes (T1D). MATERIALS AND

methodsDEPICT-1 and -2 were randomized, double-blind, parallel-group, 24-week studies, with 28-week extension periods. Adults with T1D and HbA1c 7.5%-10.5% were randomized (1:1:1) to receive dapagliflozin 5 mg, 10 mg or placebo. The short- and long-term efficacy and safety of dapagliflozin were examined in an exploratory pooled analysis of both studies.

resultsEfficacy analyses included 530, 529 and 532 and safety analysis included 548, 566 and 532 patients in the dapagliflozin 5 mg, 10 mg and placebo groups, respectively. Baseline characteristics were similar between treatment groups. At week 24, reductions were seen with dapagliflozin 5 and 10 mg compared with placebo in HbA1c (-0.40%, -0.43% vs. 0.00%) and body weight (-2.45, -2.91 vs. 0.11 kg). HbA1c and body weight reductions versus placebo were also seen after 52 weeks of treatment. There was no imbalance in occurrence of severe hypoglycaemic events between groups. The proportion of patients experiencing definite diabetic ketoacidosis (DKA) was higher with dapagliflozin 5 mg (4.0%) and 10 mg (3.5%) compared with placebo (1.1%) over 52 weeks; most events were of mild or moderate severity, and all resolved with treatment.

conclusionsOver 52 weeks, dapagliflozin provided glycaemic and weight benefits, with no increased frequency of severe hypoglycaemia compared with placebo. More DKA events were reported with dapagliflozin than placebo, highlighting the importance of appropriate patient selection, education and risk-mitigation strategies.

Indexed as

Diabetes Mellitus, Type 1AdultBenzhydryl CompoundsDouble-Blind MethodDrug Therapy, CombinationGlucosidesGlycated HemoglobinHumansHypoglycemic AgentsTreatment OutcomeBenzhydryl CompoundsdapagliflozinGlucosidesGlycated HemoglobinHypoglycemic Agentsdapagliflozin, DEPICT, DKA, insulin adjunct, long-term data, severe hypoglycaemia, SGLT-2 inhibitor, T1D

Identifiers

PMID33145944
PMCPMC7839492
OpenAlexW3096958617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.